GTx, Inc. Securities Litigation

If you purchased a significant amount of shares of GTx, Inc. (NASDAQ: GTXI), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:GTx, Inc.
Date Filed:April 10th, 2019
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:March 7th, 2019
Class End Date:April 10th, 2019

According to the Complaint, GTx is a biopharmaceutical company dedicated to the discovery, development, and
commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions.

This action stems from a proposed transaction announced on March 7, 2019 (the "Proposed Transaction"), pursuant to which GTx, Inc. will merge with Oncternal Therapeutics, Inc.

On April 8, 2019, Defendants filed a Form S-4 Registration Statement (the "Registration Statement") with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for GTx, Inc.

First Identified Complaint

Earl M. Wheby, Jr. , et al. v. GTx, Inc., et al.

Date Filed:April 10th, 2019
Class Period Start:March 7th, 2019
Class Period End:April 10th, 2019
First Identified Complaint Filings
#Document TitleFiling Date